NCT05172024

Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)

Completed Last updated 15 December 2025

What this trial tests

trial in SARS-CoV2 Infection in 15,172 participants. Completed in 31 October 2025.

Timeline

29 October 2021

Primary endpoint
31 October 2025

31 October 2025

Quick facts

Lead sponsor	NYU Langone Health
Status	Completed
Study type	OBSERVATIONAL
Enrollment	15,172
Start date	29 October 2021
Primary completion	31 October 2025
Estimated completion	31 October 2025
Sites	86 locations across Puerto Rico, United States

Conditions studied

• SARS-CoV2 Infection — all drugs for SARS-CoV2 Infection →

Sponsor

NYU Langone Health — full company profile →

Who can join

18 and older, any sex, with SARS-CoV2 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a combined retrospective and prospective, longitudinal, observational meta-cohort of individuals who will enter the cohort with and without SARS-CoV-2 infection and at varying stages before and after infection. Individuals with and without SARS-CoV-2 infection and with or without Post-Acute Sequelae of COVID-19 (PASC) symptoms will be followed to identify risk factors and occurrence of PASC. This study will be conducted in the United States and subjects will be recruited through inpatient, outpatient, and community-based settings. Study data including age, demographics, social determinants of health, medical history, vaccination history, details of acute SARS-CoV-2 infection, overall health and physical function, and PASC symptom screen will be reported by subjects or collected from the electronic health record using a case report form at specified intervals. Biologic specimens will be collected at specified intervals, with some tests performed in local clinical laboratories and others performed by centralized research centers or banked in the Biospecimen Repository. Advanced clinical examinations and radiologic examinations will be performed at local study sites with cross-site standardization.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Researching COVID to Enhance Recovery (RECOVER) adult study protocol: Rationale, objectives, and design.
   Horwitz LI, Thaweethai T, Brosnahan SB, Cicek MS, et al · · 2023 · cited 62× · PMID 37352211 · DOI 10.1371/journal.pone.0286297
2. Long COVID: Complications, Underlying Mechanisms, and Treatment Strategies.
   Zadeh FH, Wilson DR, Agrawal DK. · · 2023 · cited 36× · PMID 37388279 · DOI 10.26502/ami.93650103
3. Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort.
   Erlandson KM, Geng LN, Selvaggi CA, Thaweethai T, et al · · 2024 · cited 34× · PMID 39133923 · DOI 10.7326/m24-0737
4. Maternal and neonatal outcomes following SARS-CoV-2 infection.
   Boettcher LB, Metz TD. · · 2023 · cited 32× · PMID 37105860 · DOI 10.1016/j.siny.2023.101428
5. Incidence and Prevalence of Post-COVID-19 Myalgic Encephalomyelitis: A Report from the Observational RECOVER-Adult Study.
   Vernon SD, Zheng T, Do H, Marconi VC, et al · · 2025 · cited 30× · PMID 39804551 · DOI 10.1007/s11606-024-09290-9
6. Post-Acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) After Infection During Pregnancy.
   Metz TD, Reeder HT, Clifton RG, Flaherman V, et al · · 2024 · cited 12× · PMID 38991216 · DOI 10.1097/aog.0000000000005670
7. Distinct temporal trajectories and risk factors for Post-acute sequelae of SARS-CoV-2 infection.
   Chen C, Parthasarathy S, Leung JM, Wu MJ, et al · · 2023 · cited 6× · PMID 37908849 · DOI 10.3389/fmed.2023.1227883
8. SARS-CoV-2 humoral immunity is associated with elevated hemoglobin A1c.
   Palmer-Toy DE, Yan R, Narwaney KJ, Legaspi A, et al · · 2026 · PMID 41147485 · DOI 10.1093/labmed/lmaf036